ABSTRACT
BACKGROUND The rising breakthrough infections caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, especially Omicron and its sub-lineages, have raised an urgent need to develop broad-spectrum vaccines against coronavirus disease 2019 (COVID-19). We have developed a mosaic-type recombinant vaccine candidate, named NVSI-06-09, having immune potentials against a broad range of SARS-CoV-2 variants.
METHODS An ongoing randomized, double-blind, controlled phase 2 trial was conducted to evaluate the safety and immunogenicity of NVSI-06-09 as a booster dose in subjects aged 18 years and older from the United Arab Emirates (UAE), who had completed two or three doses of BBIBP-CorV vaccinations at least 6 months prior to the enrollment. The participants were randomly assigned with 1:1 to receive a booster dose of NVSI-06-09 or BBIBP-CorV. The primary outcomes were immunogenicity and safety against SARS-CoV-2 Omicron variant, and the exploratory outcome was cross-immunogenicity against other circulating strains.
RESULTS A total of 516 participants received booster vaccination. Interim results showed a similar safety profile between NVSI-06-09 and BBIBP-CorV booster groups, with low incidence of adverse reactions of grade 1 or 2. For immunogenicity, by day 14 after the booster vaccination, the fold rises in neutralizing antibody geometric mean titers (GMTs) from baseline level elicited by NVSI-06-09 were remarkably higher than those by BBIBP-CorV against the prototype strain (19.67 vs 4.47-fold), Omicron BA.1.1 (42.35 vs 3.78-fold), BA.2 (25.09 vs 2.91-fold), BA.4 (22.42 vs 2.69-fold), and BA.5 variants (27.06 vs 4.73-fold). Similarly, the neutralizing GMTs boosted by NVSI-06-09 against Beta and Delta variants were also 6.60-fold and 7.17-fold higher than those boosted by BBIBP-CorV.
CONCLUSIONS A booster dose of NVSI-06-09 was well-tolerated and elicited broad-spectrum neutralizing responses against SARS-CoV-2 prototype strain and immune-evasive variants, including Omicron and its sub-lineages. The immunogenicity of NVSI-06-09 as a booster vaccine was superior to that of BBIBP-CorV. (Funded by LIBP and BIBP of Sinopharm; ClinicalTrials.gov number, NCT05293548).
Competing Interest Statement
Y.K.Y., T.Y., M.L., X.Z., C.Q., D.Y.L., Z.N.W., J.L.Y., L.Q., Y.T.Z. and X.M.Y. are employees of the China National Biotec Group Company Limited. Y.L., X.F.Z., Y.K., Y.Q.J., J.W.H., JingZ.(NVSI), Z.H.L., H.Z., S.S., Z.M.L., N.L., X.Z., J.G.S., S.S.Y., X.F.C., Y.T., F.J.S., J.J.W., Z.B.H., L.F.D., F.T., S.C., Z.J.M., F.Z., Y.N.H., X.Y.L., X.L. and Q.M.L. are employees of the National Vaccine and Serum Institute (NVSI). X.J.G. and X.Y.M. are employees of Lanzhou Institute of Biological Products Company Limited (LIBP). H.W. and JinZ. are employees of Beijing Institute of Biological Products Company Limited (BIBP). Q.M.L., JingZ.(NVSI), Y.L., J.G.S., L.F.D., F.T., S.S., X.F.Z., Z.H.L., Z.M.L., Z.B.H., N.L., Y.Q.J., H.Z., J.W.H., Y.N.H., Z.J.M., S.C., F.Z. and F.J.S. are listed as inventors of the pending patent application for NVSI-06-09 vaccine (Application number: 202210083654.X). The other authors declare no competing interests.
Clinical Trial
NCT05293548
Funding Statement
The study was funded by Lanzhou Institute of Biological Products Co., Ltd. (LIBP) of Sinopharm, and Beijing Institute of Biological Products Co., Ltd. (BIBP) of Sinopharm.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The trial was reviewed and approved by the Abu Dhabi Health Research and Technology Ethics Committee of the United Arab Emirates.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵✉ e-mail: zhangyuntao{at}sinopharm.com; yangxiaoming{at}sinopharm.com; wugz{at}ivdc.chinacdc.cn; liqiming189{at}163.com
Data Availability
The clinical trial is still ongoing, and the data will be available when the trial is complete upon request to the corresponding author (Q.M.L.). After study proposals are approved, data can be shared through secure online platforms.
